New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

Ziihera (zanidatamab-hrii)

This specialty medication is authorized and manufactured internationally and is not registered or commercially distributed for retail sale in India. To verify patient eligibility, check international supply availability, or understand the regulatory logistics and documentation process: Call our Compliance Desk at 9891296838 or Email your Inquiry query@southdelhipharma.com.

ZIIHERA is a bispecific HER2-directed antibody that is used to treat adults with previously treated, unresectable or metastatic HER2-positive (immunohistochemistry [IHC 3+]) biliary tract cancer (BTC), as detected by an FDA-approved test.

Brand Name: Ziihera
Active Ingredient: zanidatamab-hrii
Dosage Forms And Strengths: For injection: 300 mg lyophilized powder in a single-dose vial.
Manufacturer: Jazz Pharmaceuticals Ireland Limited
FDA-approved use on approval date: Treatment of unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer.
Price: On Request

Do you need this medicine in India?

To help you get this medicine – Ziihera (zanidatamab-hrii), a prescription from the Registered Medical Practitioner (RMP) is required. Contact Mr. Tarun at 9891296838 via Call or WhatsApp for availability in India.

Category
Category

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

South Delhi Pharma is dedicated to facilitating access to critical, globally approved pharmaceutical therapies tailored to individual patient needs. Established in 1996, It has built a trusted reputation for assisting patients and healthcare institutions in navigating the regulatory frameworks required to securely source high-quality, international life-saving medications.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

Query Form

This is an inquiry and facilitation request form. Submission does not constitute a sale, purchase order, or guarantee of medicine availability.

Description

Zanidatamabis indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer, as detected by an FDA-approved test.

The most common adverse reactions include diarrhea, infusion-related reaction, abdominal pain, and fatigue.

Zanidatamab was approved for medical use in the United States in November 2024. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

ZIIHERA® (zanidatamab-hrii) for injection, for intravenous use. Initial U.S. Approval: 2024

See full prescribing information : Click Here

Get Access To Ziihera (zanidatamab-hrii) and Oral Suspension In India On Request

Brand Name “Ziihera” or Generic Name “zanidatamab-hrii” can be imported for personal use under “Named Patient Program” treatment in Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, Noida, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Jaipur, Aurangabad, Pune, Bangalore, Hyderabad, Chennai, Visakhapatnam, Coimbatore, Andhra Pradesh, Karnataka, Kerala, Lakshadweep, Puducherry, Tamil Nadu, Telangana, India. Contact us at support@southdelhipharma.net, southdelhipharma@gmail.com or  you can call at 9891296838 or WhatsApp at 9891296838

Related Products